CoreValues Alpha Greater China Growth ETF (CGRO)

CGRO — Key facts

What it holds	50–100 large and mid-cap Chinese and Hong Kong-listed companies
Geographic focus	Mainland China, Hong Kong, Taiwan exposure
Sector tilts	Technology, consumer discretionary, healthcare
Currency exposure	Chinese yuan, Hong Kong dollar
Active or passive	Actively managed; stock-picking driven
Typical holdings	Internet platforms, semiconductor designers, biotech, consumer brands
Primary risk	China regulatory risk, currency volatility, geopolitical tension

CoreValues Alpha Greater China Growth ETF — trading as CGRO — concentrates on the largest and most dynamic segment of the Asian equity market: publicly listed companies in mainland China, Hong Kong, and Taiwan that are either domestic champions or global competitors in technology, consumer, and healthcare sectors. The fund’s thesis is straightforward: China has been the fastest-growing major economy for two decades, and that structural momentum — rising incomes, urbanization, technology adoption, shifting consumer habits — will continue to benefit companies at the cutting edge of those shifts.

The portfolio typically holds 50 to 100 stocks, a deliberately concentrated number relative to the thousands of Chinese listed companies available. That concentration reflects active management: the fund’s team selects specific names based on conviction about growth prospects, competitive positioning, and valuation. You might find a e-commerce platform dominating rural online shopping, a semiconductor designer making chips for electric vehicles, a biopharmaceutical company creating cancer therapeutics, a luxury apparel brand capturing younger consumers’ shift away from international labels toward local brands. The common thread is growth that outpaces the broader Chinese economy.

The opportunity thesis. China’s middle class has expanded by hundreds of millions of people in the past 15 years, and many of those new consumers are still in the early stages of their purchasing journey. Discretionary spending on consumer goods, healthcare, and technology is growing faster than developed markets can match. Companies native to China and optimized for Chinese consumers often beat Western competitors at capturing that growth. A Chinese e-commerce platform running logistics hubs optimized for 200-million-person clusters operates at scales and speeds that no Western company matches. A Chinese biotech firm designing cancer drugs for Asian genetic profiles solves problems Western pharma may not prioritize. That local optimization creates genuine competitive advantage.

Size and concentration. CGRO is meaningful but not enormous — smaller than the broadest emerging-markets indices. That size allows the managers to hold meaningful positions (2–5 percent per name) in companies they understand deeply, without being forced into mega-cap weightings. But it also means you bear concentration risk; if a single name crashes, it will dent the fund noticeably.

Currency exposure. Holdings are denominated in Chinese yuan and Hong Kong dollars. If the dollar strengthens against those currencies, your returns are diminished in dollar terms; if it weakens, returns are amplified. Some investors see currency as an additional source of return; others find it distracting noise. CGRO does not hedge by default — you are bearing the full currency impact.

Regulatory and political risk. This is the elephant in the room. Chinese companies answer to the Chinese government, which controls capital flows, internet content, data, and corporate governance in ways foreign investors are often uncomfortable with. Regulatory crackdowns on technology giants (especially after the 2020–2021 antitrust wave), on private education, and on offshore listings have vaporized billions of investor capital. A shift in Beijing’s priorities can instantly reset the investment case for a whole sector. Geopolitical tension between the United States and China raises the risk of sanctions, forced delistings, or restrictions on American investors owning Chinese equities. None of this is theoretical — it has happened repeatedly.

Valuation and sentiment. Chinese growth stocks command premium valuations, in part because growth is genuine and in part because sentiment swings violently. When foreign capital is chasing China, valuations run hot. When regulatory fears spike or geopolitical tension rises, valuations crash. An investor needs to understand their own comfort with that volatility — CGRO can swing 30–50 percent in a bad year and 50–100 percent in a strong one.

The liquidity picture. CGRO itself trades with good liquidity on most U.S. exchanges — the ETF is easy to buy and sell. But the underlying Chinese holdings may be less liquid, especially if you are holding a very large position. In a severe market stress, that illiquidity could mean wider spreads or slow execution for giant orders.

Active management angle. CGRO’s managers hunt for specific growth stories within China. They screen for companies with sustainable competitive advantages, management quality, and valuations not yet reflected in the price. They can exit positions when fundamentals deteriorate — an advantage over a passive index, where a broken company stays until its market cap shrinks enough to fall out. But that edge only manifests if the managers are actually better at stock-picking than the market; overconfidence in that belief is a common failure mode.

What to watch. Regulatory changes from Beijing and impact on specific holdings. Earnings growth in key positions versus consensus expectations. Currency movements and implications for returns. Capital Group’s track record in China specifically — how have their other China-focused strategies performed versus benchmarks and versus peers. Geopolitical headlines and whether U.S.-China relations are easing or deteriorating.

Who should own CGRO. Investors with conviction that China’s long-term growth trajectory remains intact despite near-term regulatory and political noise. Investors who can live with 35–50 percent annual volatility and who plan to hold for at least 5–10 years. Not suitable for short-term traders, for investors who cannot tolerate geopolitical risk, or for anyone needing the money within a few years. The fund is a long-term conviction bet, not a diversified building block of a core portfolio.